Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment, has announced that it has received notifications from option holders to exercise their options. The exercise of these options will result in the issuance of new ordinary shares in the company. The exercise price for the 2015B options is EUR 2.90 per share, while the exercise price for the 2015D options is EUR 1.09 per share.
The company plans to apply for the admission of the new ordinary shares to trading on the London Stock Exchange and Nasdaq Helsinki. The admission is expected to occur on or around October 30, 2023, following the issue and registration of the new shares on or around October 31, 2023. The new ordinary shares will rank pari passu with the existing ordinary shares of the company.
After the registration of the new shares, Faron's total issued number of shares will be 68,786,699 ordinary shares with voting rights attached. The company does not have any shares in treasury. Shareholders can use this figure as the denominator for calculating their interest in the issued shares and votes of the company.
For more information, investors can contact LifeSci Advisors, Cairn Financial Advisers LLP, Peel Hunt LLP, or Sisu Partners Oy, which is the certified adviser on Nasdaq First North.
Faron Pharmaceuticals is a biopharmaceutical company that focuses on developing novel immunotherapies for the treatment of cancer.